Yaegashi, Mizunori http://orcid.org/0000-0003-0599-8351
Iwaya, Takeshi
Sasaki, Noriyuki
Fujita, Masashi
Ju, Zhenlin
Siwak, Doris
Hachiya, Tsuyoshi
Sato, Kei
Endo, Fumitaka
Kimura, Toshimoto
Otsuka, Koki
Sugimoto, Ryo
Sugai, Tamotsu
Liotta, Lance
Lu, Yiling
Mills, Gordon B.
Nakagawa, Hidewaki
Nishizuka, Satoshi S. http://orcid.org/0000-0001-9178-790X
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (JSPS 16K19951, JSPS 17K10605, JSPS 19K09130, JSPS 18K15326, JSPS 19K09224, JSPS 15KK0317)
JSPS Fujita Memorial Fund for Medical Research
Ministry of Education, Culture, Sports, Science and Technology (16H01578)
Keiryoukai Research Grant #136 and Iwate Prefectural Regional Innovation Grant.
Article History
Received: 7 July 2020
Revised: 7 December 2020
Accepted: 5 January 2021
First Online: 3 March 2021
Ethics approval and consent to participate
: This study was performed in accordance with the Declaration of Helsinki. All samples were acquired after obtaining written informed consent and approval by the Institutional Review Board of Iwate Medical University School of Medicine.
: Not applicable.
: Underlying data are available here: Gene sequencing panel: NBDC Human Database (ExternalRef removed) Submission: JGA00000000284 Study: JGAS00000000243 Dataset: JGAD00000000343 RPPA data: The University of Texas MD Anderson Cancer Center RPPA data repository URL: ExternalRef removed Accession ID: TCPA00000006-1.
: S.S.N.: Grant/Research Support, Array Jet, Taiho Pharmaceuticals, Boehringer-Ingelheim, Geninus; Honorarium, Chugai Pharmaceuticals; Consultation, Mills Institute for Personalized Care (MIPC), Nomura Jimusyo; Advisor, CLEA Japan. T.I.: Grant/Research support, Nippon Kayaku, Chugai Pharmaceutical, Daiichi Sankyo. G.B.M.: Consultant/Scientific Advisory Board, AstraZeneca, ImmunoMET, Ionis, Lilly USA, LLC, PDX Pharma, Signalchem Lifesciences, Symphogen, Tarveda; Sponsored Research, AstraZeneca, Karus Therapeutics, Nanostring, Pfizer, Tesaro; Stock/Options/Financial, ImmunoMET, Tarveda, Catena Pharmaceuticals, SignalChem, Spindletop Ventures; Travel reimbursement only, Chrysalis, MIPC, Nuevolution; Licensed Technology, HRD assay to Myriad Genetics, DSP to Nanostring. The remaining authors declare no competing interest.
: This study is supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grant 16H01578, 15KK0317, 19K09224, 19K09130, 17K10605, 18K15326, 16K19951; JSPS Fujita Memorial Fund for Medical Research; Keiryoukai Research Grant #136 and an Iwate Prefectural Regional Innovation Grant.